GenScript is best known for its gene synthesis capabilities, which we estimate is more than half of the life science services and products segment. In 2014, GenScript was the leader in gene synthesis, ...

PISCATAWAY, N.J., Aug. 27, 2024 /PRNewswire/ -- Legend Biotech (LEGN), a subsidiary of GenScript Biotech Corporation (hereinafter referred to as "GenScript"), a global leader in life sciences research ...

In the rapidly evolving world of cancer treatments, CAR-T cell therapy stands out for its effectiveness tackling hematologic tumors. Booming demand for such therapies powered Legend Biotech Corp. LEGN ...

R&D Innovation to Lead the Future, Deepening Customer Value Creation From the performance during the 2023 reporting period, GenScript Group's overall development is optimistic, with each business ...

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation ...

PISCATAWAY, N.J., Aug. 8, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global leader in life sciences innovation, today unveiled its new global brand platform: Scripting ...

PISCATAWAY, N.J., Sept. 12, 2024 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript"), a global leader in life sciences products and services, announced the appointment of Dr. Ross Allen ...

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, ...

Conference to convene gene- and cell-therapy thought leaders from the research, industry, and capital communities as well as representatives from regulatory bodies PISCATAWAY, N.J., Dec. 14, 2023 ...

PISCATAWAY, N.J., Jan. 7, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences research and manufacturing services, has officially joined the Pharmaceutical Supply ...

Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding ...